Abstract: A system for preparation of an implant and ab interno insertion of the implant into an eye including a handle having one or more actuators and an elongated shaft having an outer sheath and an elongate member positioned within a lumen of the tubular outer sheath. The system includes a recess sized for holding a patch of material fixed relative to the handle and a cutting member movable relative to the handle and to the recess. The cutting member cuts the patch of material into an implant as the cutting member moves towards a cutting configuration. The implant, once cut, is axially aligned with the lumen of the tubular outer sheath. The inner elongate member is movable relative to the tubular outer sheath to advance the implant into a deployment position in the lumen of the tubular outer sheath for delivery into the eye. Related devices and methods are provided.

Abstract: A capsulorhexis device is inserted into an incision site of a cornea to make an incision in an anterior capsule surrounding a crystalline lens. The capsulorhexis device includes a loop having elasticity and conductivity; a moving member having one end fixed and coupled to the loop; an insertion guide configured so that, while the incision is being made in the crystalline lens capsule, a front end thereof is inserted into the incision site of the cornea; and a housing having one end coupled to a rear end of the insertion guide, wherein the loop is housed in the housing and, to make the incision in the crystalline lens capsule, slides in the housing together with the moving member to pass through the insertion guide and be deployed into an anterior chamber of the eye.

Abstract: Protective eyewear lens assemblies include one or more metal-detectable components and a lens body. The lens body is formed from a polymeric material and the one or more metal-detectable component are permanently encapsulated on, along or within the lens body. Protective eyewear including such lens assemblies and methods of manufacture are also included.

Abstract: A rescue litter relates generally to a person, animal, and provisions carrying apparatus for purposes of human or animal recovery and relief missions. The carrying apparatus has commonalities with portable beds. The rescue litter aids manually carrying a casualty. The rescue litter comprises a stretcher sheet. The rescue litter also comprises at least one strap along the stretcher sheet to support the weight of the casualty. The stretcher sheet comprises guides to direct progressive motion of the strap(s) from a strap holder on the stretcher sheet where the strap(s) is/are held, to a head end where the strap(s) is/are free to grasp.

Abstract: A medical suspension bridge includes a cross beam, a suspension pipe and a moving module. The cross beam is connected with the suspension pipe. The moving module is movably connected with the cross beam. The cross beam includes a load-bearing beam. The moving module includes a cable carrier moving plate extending to the upper portion of the load-bearing beam. The medical suspension bridge further includes a cable carrier. One end of the cable carrier is connected to the load-bearing beam, and the other end is connected to the cable carrier moving plate. Since cables such as electric wires and air pipes within a box body which needs to be moved are collectively mounted within the cable carrier, not only the routing is more tidy, but also the cables can be well protected.

Abstract: An operating table is proposed that may form a system with a remote control. The operating table has a column and table top comprising at least three elements, at least two of which are movable. Interface joints (401-403) are provided between adjacent elements and are controlled to move by a controller (100). A light emitting arrangement (42) is arranged at each interface joint and is adapted to display light in a pattern having a characteristic that is visibly unique to the associated interface joint such that the interface joints are visually distinguishable from one another. The remote control (50) has touch controls (601-603) for communicating signals for controlling movement of the interface joints (401-403). Each touch control is associated with one interface joint and is provided with a visible pattern having a characteristic that is substantially the same as that displayed at the associated interface joint.

Abstract: A surgical platform and trolley assembly and an interface of a robotic system are provided. The surgical platform and trolley assembly includes a trolley portion and a surgical platform portion. The trolley portion supports the surgical platform portion, and affords positioning and repositioning of the surgical platform portion relative to the interface of the robotic system. An end portion of the surgical platform portion is attachable relative to the robotic system via engagement to the interface.

Abstract: Caskets, cap panel assemblies for a casket, and methods for manufacturing cap panel assemblies are described. A casket may include a casket shell, at least one casket cap pivotally mounted on the casket shell, and a cap panel assembly mounted in the at least one casket cap. The cap panel assembly may include a cap panel, a puffing member attached to each edge of the cap panel, a cap panel insert positioned in-line with the cap panel, and a plurality of resilient members positioned on a front face of the cap panel insert. The plurality of resilient members may be tensioned, for example, to hold keepsakes, memorabilia, or other types of objects on or in the cap panel insert. The cap panel insert can include a mounting bracket or a screw and wire assembly for mounting the cap panel insert on a wall.

Abstract: A hybrid passenger vehicle includes a chassis supported by at least one front wheel and at least one rear wheel, a body coupled to the chassis including at least one door, and a vehicle floor coupled to the chassis. The body defines an interior space configured to be occupied by at least one passenger when operating the vehicle, and the vehicle floor has a front end and a rear end. A rear wall is coupled to the rear end of the vehicle floor such that the rear wall defines a rearmost boundary of the vehicle floor. A rear suspension assembly is coupled to the chassis. The rear wall is arc-shaped, and the rear suspension assembly is located rearward of the rear wall.

Abstract: A litter lift system includes a winch system and a lifting strap. The winch system includes a rotatable spool. The lifting strap has a first end, a second end, and an intermediate segment extending away from the lifting strap between the first end and the second end. The first end is coupled to the rotatable spool such that rotation of the spool in a first direction winds the lifting strap about the spool and rotation of the spool in a second direction unwinds the lifting strap from the spool. The second end defines a first lifting segment and the intermediate segment defines a second lifting segment. The first lifting segment and the second lifting segment are each forked to define two separate lifting loops.

Abstract: An electric wheelchair includes a main frame; a drivable wheel supported by the main frame; an electric motor disposed on the main frame and configured to drive the drivable wheel; a clutch configured to switch a power transmission path from the electric motor to the drivable wheel between an engagement state and a disengagement state; and a clutch operation handle configured to be moved in a predetermined range in an up-down direction. The clutch operation handle is configured to operate the clutch so as to be in: (i) one of the engagement state or the disengagement state when the clutch operation handle is stopped at a lowest position of the predetermined range; and (ii) the other of the engagement state or the disengagement state when the clutch operation handle is stopped at a highest position of the predetermined range.

Abstract: A therapeutic device comprises an upper massage surface having a generally central spinous channel, a first domed portion on a first lateral side of the central spinous channel and a second domed portion on a second lateral side of the central spinous channel. The device has a lower base surface, a front edge, and a rear edge, with the upper massage surface extending between front edge and the rear edge. The device further has a first lateral edge on one side of the therapeutic device and a second lateral edge on an opposing side of the therapeutic device, such that the distance between the first and second lateral edges is greater than the distance between the front edge and the rear edge.

Abstract: A penis massager includes a housing defining a first space and a second space therein, a sleeve provided in the first space of the housing, a driving motor mounted in the second space of the housing, and at least two handles extending outwardly from an outer face of the housing for holding of the penis massager. The sleeve defines an interior volume for accommodating a penis therein. The driving motor is connected to the sleeve in a transmission way, configured for driving to sleeve to move and/or rotate relative to the housing, thereby providing a massaging stimulation to the penis in the sleeve.

Abstract: A muscle memory training apparatus restores muscle memories that have become aberrant to previous normal or superior performance. It restores reflex stabilization muscle memories thereby providing a stable platform upon which voluntary muscle memories are restored. It is based on the universally accepted fact that muscle memories may be improved with practice and the yet to be accepted fact that reflexes execute muscle memories that may likewise be improved. The apparatus generates movements, perturbations, that are applied to the user; thereby stimulating reflex sensory neurons, effectuating stabilization reflexes, executing reflex muscle memories, and contracting muscles that countervail the apparatus perturbations. The perturbations and thereby the execution of the muscle memories is repeated over a protracted period and practiced multiple times per second. Practice improves the performance of the stabilization reflexes thereby restoring stabilization.

Abstract: Actuators and methods of use are provided. An actuator may include an inner member made from an elastic material and defining a compartment for receiving an actuating fluid, the inner member being moveable in a longitudinal direction from a relaxed state to an expanded state by introducing an actuating fluid into the inner member; and an outer member made from an inelastic material and being disposed around the elastic inner member to control expansion of the elastic inner member in a radial direction, the outer member being moveable from a folded relaxed configuration to an unfolded extended configuration as the inner member moves from the relaxed state to the expanded state, wherein the movement of the actuator between the relaxed state and the expanded state causes a movement of a structure to which the actuator is attached.

Abstract: Disclosed embodiments include a stair step assisting device which aids a user, recovering from surgery or having an injury which prevents bearing weight on one foot or ankle, in climbing or descending a staircase. The stair step assisting device has a main body, a lower body and an upper body, which in some embodiments are adjustable relative to one another to accommodate heights of different users and/or different riser heights of different staircases. The device includes lower and upper tread interface surfaces which rest on treads of two adjacent steps, and lower and upper riser interface surfaces which are positioned against risers of two adjacent steps.

Abstract: A system is described, for rehabilitating the walk comprising an active exoskeleton with a supporting structure for right leg and left leg, bearing and moving structures of femur, tibia and foot of the patient, a weight supporting device for patient and active exoskeleton, the weight supporting device ending with a structure connected to means for supporting exoskeleton and patient, handling means connected to the weight supporting device to allow its movement, means for transmitting to the weight supporting device electric and pneumatic supplies and electric signals for managing, controlling, monitoring and diagnosing the system, a managing system comprising a microprocessor for acquiring and processing data, and managing a motion neuro-rehabilitation session; a weight supporting device for a system for rehabilitating the walk is further described.

Abstract: A lift system has a back panel and a seat panel to provide a seat for a user. The back panel is slidably mounted on a support column via slider so that the back panel can be moved up and down to adjust the seat height. The seat panel can be flipped back to accommodate a user in a standing posture. With the support column, the lift system can be attached to a wheeled frame, a pole, a rotatable arm, a wall or a ceiling depending on the need of the user.

Abstract: Disclosed is a device for providing resuscitation or suspended state through redistribution of cardiac output to increase supply to the brain and heart for a patient. The device includes an electrically controllable redistribution component attachable to the patient to provide redistribution of the cardiac output to increase supply to the brain and heart. The redistribution component, following a predefined reaction pattern based on an electrical signal, and computer means configured to: receive a patient data which identifies physiological and/or anatomical characteristics of the patent; and provide the electrical signal for the redistribution component based on the patient data or a standard response. The device may provide mechanisms to protect the aorta and the remaining anatomy of the patient from inadvertent damage caused by the disclosed device in any usage scenario of either correct intended usage or unintended usage. Also disclosed is a method for providing resuscitation or suspended state.

Abstract: A container for transporting and/or processing a biopharmaceutical fluid, the container comprising a wall, the wall comprising a shape memory material being adapted to change shape when induced by an external stimulus, so that the container can be alternately in a collapsed state and in an unfolded state, the wall of the container in the unfolded state delimiting an internal cavity adapted to contain the biopharmaceutical fluid.

Abstract: A robotic system and method are provided for transfer of fluid between a container accessible via a container-septum and a fluid transfer assembly accessible via a fluid transfer connector septum. The robotic system includes a controller and a manipulator controllable by the controller to manipulate at least one of the container and the fluid transfer assembly. The controller is configured to operate the manipulator to secure contact between the container-septum and the fluid transfer connector septum during at least a portion of the transfer of the fluid.

Abstract: A system for connecting containers which is intended for the temporary assembly of a first and a second container, said connection system comprising a closing sleeve, provided with a first part suitable for being mounted on the first container, and said closing sleeve also being provided with a second part which is suitable for allowing the temporary mounting of the opening of the second container and a membrane separating said first and said second part of said closing sleeve, said membrane being suitable for being perforated by the second container during the mounting of the latter on the second part of the closing sleeve, characterised in that said connection system comprises a lid intended for closing off the second part of the closing sleeve before the connection system is used, said lid and said closing sleeve being obtained by means of a simultaneous method of moulding by injection of at least one plastic material, the lid being mounted on the second part of the closing sleeve once the lid and the clos

Abstract: Suggested is a pacifier, comprising a mouthpiece and a shield further including a vibration-generating device.

Abstract: A drinking straw having an internal coating for delivery of an active agent when the straw is used to consume a beverage is provided. The active agent includes sweetener, flavour, a nutrient and/or a pharmaceutical and optionally colour. The coating is prepared by mixing a modified cellulose with water to form a paste or gel. The coating is then used to coat the inside surface of a drinking straw to a thickness of up to 1 mm. The coating is dried to reduce the water content to less than 5% by weight. Liquid drawn through the straw breaks down the modified cellulose releasing the active agent into the liquid, for consumption.

Abstract: A method for dispensing discrete medicaments with a first feeder unit includes the steps of determining a remaining value indicative of the amount of the medicaments remaining in the container; comparing said remaining value to a threshold value; making a selection between a complete empty detection mode when said remaining value is above the threshold value and a shortened empty detection mode when the remaining value is below the threshold value; and executing the selected one of the complete empty detection mode and the shortened empty detection mode when no medicament is fed from the container towards the outlet after controlling the dispensing mechanism to feed a medicament from the container into the outlet.

Abstract: A biometrically locked medication bottle lid including a bottle assembly, an alarm assembly and a lock assembly is disclosed herein. The bottle assembly includes a lid and a dispenser mechanism comprising a spring and a tray to dispense medicament. The alarm assembly includes a digital display that is attached to the front side of the bottle. A speaker and a light are also attached to the front side of the bottle and can be activated when an alarm is triggered indicating that it is time for a user to take their medication. The lock assembly includes a fingerprint sensor and a lock mechanism. The lock mechanism is actuated when the fingerprint sensor scans the fingerprint of the user.

Abstract: The invention discloses a composition comprising not less than 20% w/w bisdemethoxycurcumin for regeneration of alveolar cells damaged in emphysematous conditions and for the therapeutic management of chronic obstructive pulmonary disease and acute respiratory distress syndrome. The composition further comprises 10-35% w/w demethoxycurcumin and 10-45% w/w curcumin. The composition is very suitable for treating COPD and ARDS due to viral infections, specifically COVID 19 and for improving lung function during prognosis.

Abstract: An inhalable pharmaceutical composition comprising ketamine or its pharmaceutically acceptable salt for use in a method of treatment of depression by administration via pulmonary route, treatment comprising cycle of multiple sequences of administration by inhalation, said cycle lasting from 10 days to 30 days, wherein each of multiple sequences of administration is performed in a one single day, with 2 to 4 days intervals between sequences, and each of said sequences consists of multiple single dose inhalations separated by a break period lasting at least 5 minutes. The composition is especially useful for the treatment of treatment-resistant depression.

Abstract: The disclosure herein relates to the innovative epinephrine formulations in aqueous solution of medicinal products that enhance the physicochemical stabilities of epinephrine and extend the product shelf life. In some instances, the formulations comprise epinephrine or a salt thereof, a complexing agent, and a “non-sulfite” antioxidant. The epinephrine formulations substantially demonstrated the superior physicochemical stabilities to conventional sulfite formulation of commercial medications currently available. In some instances, sulfite-free formulations further provide further benefit (e.g., safety benefits) to sulfite-sensitive patients. The compositions, methods for preparing the formulations, and methods of using the same (e.g., in the treatment of anaphylaxis) are also provided.

Abstract: Methods of treatment in subjects suffering from diabetes mellitus or obesity are provided. The methods comprise ablation of a region of the small intestine in the subject, in particular ablation of a region of the duodenum. The ablation may be a mechanical, electrical, thermal, radiative, or chemical ablation and may in some cases target a sensory nerve. The methods may, in some cases, comprise the step of administering an active agent directly to the small intestine in the subject, in particular administering the active agent directly to the duodenum.

Abstract: The disclosure provides for means for a method to facilitate food intake and food retention in a mammal by applying a sufficient dose of a local anesthetic drug in the lumen of the pharyngeal-esophageal-gastric-duodenal tract before or during or after eating. The local anesthetic can be amethocaine, articaine, benzocaine, bupivacaine, chloroprocaine, cinchocaine, cyclomethycaine, dibucaine, diethocaine, etidocaine, larocaine, levobupivacaine, lidocaine, lignocaine, mepivacaine, novocaine, piperocaine, prilocaine, procaine, proparacaine, propoxycaine, QX-222, QX-314, ropivacaine, tetracaine, trimecaine, menthol, eugenol or a safe pharmaceutical formulations of tetrodotoxin, saxitoxin, or neosaxitoxin. The disclosure is useful for patients having problems with food intake or food retention.

Abstract: The present disclosure is concerned with substituted N-(5-chloro-4-((4-chlorophenyl)(cyano)methyl)-2-methylphenyl)benzamide compounds, and methods of treating and/or preventing neurodegenerative or neurocognitive disorders including, but not limited to, Alzheimer's disease, cerebral autosomal dominant arteriopathy with sub-cortical infarcts and leukoencephalopathy (CADASIL), Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis (ALS/Lou Gehrig's disease), Multiple Sclerosis, spinal muscular atrophy, spinal and bulbar muscular atrophy, familial spastic paraparesis, Machado Joseph disease, Friedreich's ataxia, Lewy body disease, and dementia (e.g., vascular dementia, Lewy body dementia, frontotemporal dementia, mixed dementia, dementia induced by Alzheimer's disease or Parkinson's disease). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Abstract: A bactericidal and virucidal pharmaceutical composition for use on epithelial tissues such as pulmonary, nasal and oral tissues, which comprises a non-steroidal anti-inflammatory drug (NSAID) in a concentration between 5 and 500 mM and a salt, being the NSAID preferably solubilized in a hypertonic saline solution applicable in therapies for viral infections of the Herpes simplex type. The composition can be used in therapies for herpes simplex viral infections, be used as a bactericidal mouthwash, or be vehiculated to the lung by using a nebuliser, for cystic fibrosis.

Abstract: Provided herein are fixed-dose combination formulations of a pharmaceutically effective amount of eflornithine together with a pharmaceutically effective amount of sulindac. Also provided are methods of use and of methods of manufacture of these formulations.

Abstract: The present disclosure provides a compound for use in therapeutic and/or prophylactic treatment of non-alcoholic steatohepatitis (NASH) and/or alcoholic steatohepatitis (ASH). The compound for use according to the invention, is an unsaturated fatty acid with an oxygen incorporated in the ?-position, and further comprising an ?-substituent. More particularly, the invention provides a compound for use in treatment of NASH and/or ASH, and a method using this, wherein the compound is of Formula (II), wherein RI, R2, R3, X, and Y are as defined in the specification; and wherein this compound may be administered alone or in combination with an additional active agent.

Abstract: The invention relates to nutraceutical compositions comprising dopamine transporter inhibitors and to their use as dietary supplements and food additives.

Abstract: The invention provides compositions comprising a medium chain triglyceride and a urolithin. The invention also provides uses and methods associated with, or making use of the compositions, such as a medicament, dietary supplement, functional food or medical food and in the treatment and/or prophylaxis of a muscle-related pathological condition.

Abstract: The present invention provides cyclic nitro compound, pharmaceutical compositions of cyclic nitro compounds and methods of using cyclic nitro compounds and/or pharmaceutical compositions thereof to treat or prevent diseases or disorders characterized by abnormal cell proliferation, such as cancer, inflammation, cardiovascular disease and autoimmune disease.

Abstract: The present invention relates to a pharmaceutical combination comprising a CDK inhibitor and at least one antioxidant enzyme inhibitor for use in the treatment of cancer. The present invention also relates to a method for the treatment of cancer comprising administering to a subject in need thereof, a therapeutically effective amount of a CDK inhibitor and a therapeutically effective amount of at least one antioxidant enzyme inhibitor. The pharmaceutical combination of the present invention exhibits synergistic effect when used in the treatment of cancer.

Abstract: The present disclosure relates to improved methods of treatment with nirogacestat.

Abstract: The present disclosure relates to improved methods of treatment with nirogacestat.

Abstract: The present invention pertains to a drug for the treatment and/or prevention of pain, more specifically to a medicinal preparation for external use to treat and/or prevent peripheral neuropathic pain, the medicinal preparation containing as an active ingredient N2-{[1-ethyl-6-(4-methylphenoxy)-1H-benzimidazol-2-yl]methyl}-L-alaninamide.

Abstract: The present intervention identifies the antiglycating inhibitors from a series of carbazole-linked 1,2,3 triazole derivatives through in vitro MGO-mediated glycating BSA model. Derivatives 12, and 13 established a remarkable antiglycation activity at the receptor level in human monocytes. These compounds were found non-toxic, and possess the potential to halt AGE-RAGE/ROS-mediated NF-kB-dependent COX-2, and its proinflammatory product, PGE2, production in monocytes. Hence, carbazole-linked 1,2,3 triazole derivatives provide treatment modalities to delay or prevent the onset of late diabetic micro- and macro-vascular complications in diabetic patients.

Abstract: The invention provides compositions and methods for treating conditions associated with decreased activity of hydrogen sulfide.

Abstract: The present disclosure relates to methods of administering Compound I for treating fibrotic disorders, inflammatory disorders or autoimmune disorders.

Abstract: A method of treating chemical-induced lung injury in a subject in need thereof includes administering to the subject a therapeutically effective amount of ibudilast, or a pharmaceutical salt thereof.

Abstract: Disclosed herein are novel formulations containing relacorilant ((R)-(1-(4-fluorophenyl)-6-(1-methyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-hexahydro-1H-pyrazolo[3,4-g]isoquinolin-4a-yl)(4-(trifluoromethyl)pyridin-2-yl)methanone) that are suitable for administration, including oral administration, to patients suffering from disorders amenable to treatment by glucocorticoid receptor modulators (GRMs). Single unit dosage forms comprise softgel capsules containing these formulations. Such softgel capsules may contain, e.g., relacorilant formulations containing 25 milligrams (mg), 50 mg, 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, or other amounts of relacorilant. These novel formulations and single unit dosage forms may be used to treat diseases and disorders including Cushing's syndrome, Cushing's Disease, and other disorders.

Abstract: This invention discloses uses for nicardipine in preparing anti-lung cancer products. This invention provides uses for nicardipine in the preparation of products to treat non-small cell lung cancer. From carrying out cancer drug repositioning for the FDA- and CFDA-approved drug nicardipine, experiments for this invention show, based on screening of non-anti-cancer drugs for various cancer cell lines (tissue types) and mutation sites, that nicardipine has a new use as an anti-small cell lung cancer and/or anti-non small cell lung cancer medication, thus achieving a new purpose for an old drug.

Abstract: The present application provides novel heterocyclic compounds and pharmaceutically acceptable salts thereof. Also provided are methods for preparing these compounds. These compounds are useful for inhibiting ERK1/2. By administering to a patient in need a therapeutically effective amount of one or more of the compounds of formula (I), wherein X, Y, Z, J, M, and R1 to R8 are defined herein, these compounds are effective in treating conditions associated with dysregulation of the RAS/RAF/MEK/ERK pathway. A variety of conditions can be treated using these compounds and include diseases which are characterized by abnormal cellular proliferation. In one embodiment, the disease is cancer.

Abstract: A 6?-(2-bromophenyl)-2?-methoxy-3,4?-bipyridine-3?-carbonitrile as antioxidant compound, its synthesis, and its use as an antioxidant agent.